Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Feb 11, 2026
- Amount
- $600,000
- Closes
- Nov 5, 2029 (in 1091 days)
Similar opportunities open now
- Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses May 2027Up to $500K
- NIH Research Program Projects (Parent P01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses May 2029
- Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)Same funderOpenNational Institutes of HealthCloses Oct 2029
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Jan 7, 2027 (in 58 days)Up to $500K
Classification and identifiers
- Solicitation number
- PAR-28-056
- Assistance listing (CFDA)
- 93.393
Amount
$600,000
Who can apply
State government agencies, Nonprofits, and Local government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying patients at high risk of PDAC (because of genetic factors, family history and/or the presence...